AVIBACTAM\CEFTAZIDIME: 1,655 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
1,655
Total FAERS Reports
567 (34.3%)
Deaths Reported
515
Hospitalizations
1,655
As Primary/Secondary Suspect
155
Life-Threatening
28
Disabilities
Active Ingredient: AVIBACTAM SODIUM\CEFTAZIDIME ·
First Report: 20140205 · Latest Report: 20250822
What Are the Most Common AVIBACTAM\CEFTAZIDIME Side Effects?
#1 Most Reported
Off label use
286 reports (17.3%)
#2 Most Reported
Drug ineffective
194 reports (11.7%)
#3 Most Reported
Death
187 reports (11.3%)
All AVIBACTAM\CEFTAZIDIME Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Off label use | 286 | 17.3% | 103 | 93 |
| Drug ineffective | 194 | 11.7% | 101 | 73 |
| Death | 187 | 11.3% | 187 | 11 |
| Pathogen resistance | 119 | 7.2% | 34 | 42 |
| Drug resistance | 111 | 6.7% | 42 | 48 |
| Multiple organ dysfunction syndrome | 74 | 4.5% | 66 | 22 |
| Septic shock | 74 | 4.5% | 62 | 37 |
| Acute kidney injury | 70 | 4.2% | 16 | 24 |
| Pyrexia | 66 | 4.0% | 19 | 37 |
| Condition aggravated | 62 | 3.8% | 23 | 37 |
| Treatment failure | 51 | 3.1% | 42 | 24 |
| Sepsis | 47 | 2.8% | 23 | 22 |
| Respiratory failure | 46 | 2.8% | 37 | 26 |
| Diarrhoea | 40 | 2.4% | 16 | 26 |
| Encephalopathy | 40 | 2.4% | 25 | 11 |
| Platelet count decreased | 37 | 2.2% | 6 | 8 |
| Myoclonus | 36 | 2.2% | 21 | 3 |
| Pneumonia | 36 | 2.2% | 16 | 14 |
| Renal failure | 35 | 2.1% | 10 | 19 |
| Thrombocytopenia | 34 | 2.1% | 5 | 18 |
Who Reports AVIBACTAM\CEFTAZIDIME Side Effects? Age & Gender Data
Gender: 35.4% female, 64.6% male. Average age: 56.8 years. Most reports from: CN. View detailed demographics →
Is AVIBACTAM\CEFTAZIDIME Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2014 | 5 | 0 | 2 |
| 2015 | 17 | 1 | 8 |
| 2016 | 14 | 2 | 1 |
| 2017 | 20 | 13 | 5 |
| 2018 | 75 | 36 | 33 |
| 2019 | 91 | 26 | 40 |
| 2020 | 88 | 21 | 38 |
| 2021 | 100 | 37 | 24 |
| 2022 | 113 | 17 | 47 |
| 2023 | 96 | 12 | 37 |
| 2024 | 110 | 13 | 54 |
| 2025 | 75 | 22 | 28 |
What Is AVIBACTAM\CEFTAZIDIME Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 373 |
| Pneumonia | 173 |
| Klebsiella infection | 152 |
| Pseudomonas infection | 104 |
| Infection | 82 |
| Sepsis | 75 |
| Abdominal infection | 65 |
| Anti-infective therapy | 64 |
| Pneumonia klebsiella | 57 |
| Bacterial infection | 39 |
AVIBACTAM\CEFTAZIDIME vs Alternatives: Which Is Safer?
AVIBACTAM\CEFTAZIDIME vs AVOBENZONE\HOMOSALATE\OCTINOXATE\OCTISALATE\OCTOCRYLENE\OXYBENZONE\TITANIUM DIOXIDE\ZINC
AVIBACTAM\CEFTAZIDIME vs AVOBENZONE\HOMOSALATE\OCTINOXATE\OCTISALATE\OXYBENZONE
AVIBACTAM\CEFTAZIDIME vs AVOBENZONE\HOMOSALATE\OCTISALATE\OCTOCRYLENE
AVIBACTAM\CEFTAZIDIME vs AVOBENZONE\HOMOSALATE\OCTISALATE\OCTOCRYLENE OR AVOBENZONE\HOMOSALATE\OCTISALATE\OCTOCRYLENE\OXYBENZONE
AVIBACTAM\CEFTAZIDIME vs AVOBENZONE\HOMOSALATE\OCTISALATE\OCTOCRYLENE\OXYBENZONE
AVIBACTAM\CEFTAZIDIME vs AVOBENZONE\OCTINOXATE\OCTISALATE\OXYBENZONE
AVIBACTAM\CEFTAZIDIME vs AVOBENZONE\OCTISALATE\OCTOCRYLENE
AVIBACTAM\CEFTAZIDIME vs AVOBENZONE\OCTOCRYLENE\OXYBENZONE
AVIBACTAM\CEFTAZIDIME vs AVONEX
AVIBACTAM\CEFTAZIDIME vs AXICABTAGENE CILOLEUCEL
Official FDA Label for AVIBACTAM\CEFTAZIDIME
Official prescribing information from the FDA-approved drug label.